Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor.

Gouédard L, Chen YG, Thevenet L, Racine C, Borie S, Lamarre I, Josso N, Massague J, di Clemente N.

J Biol Chem. 2000 Sep 8;275(36):27973-8.

2.

Components of the anti-Müllerian hormone signaling pathway in gonads.

di Clemente N, Josso N, Gouédard L, Belville C.

Mol Cell Endocrinol. 2003 Dec 15;211(1-2):9-14. Review.

PMID:
14656470
3.

The serine/threonine transmembrane receptor ALK2 mediates Müllerian inhibiting substance signaling.

Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingraham HA.

Mol Endocrinol. 2001 Jun;15(6):936-45.

PMID:
11376112
4.

AMH signaling: from receptor to target gene.

Visser JA.

Mol Cell Endocrinol. 2003 Dec 15;211(1-2):65-73. Review.

PMID:
14656478
5.

Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.

Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK.

Mol Endocrinol. 2001 Jun;15(6):946-59.

PMID:
11376113
6.

Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.

Donahoe PK, Clarke T, Teixeira J, Maheswaran S, MacLaughlin DT.

Mol Cell Endocrinol. 2003 Dec 15;211(1-2):37-42. Review.

PMID:
14656474
7.

Role of type I receptors for anti-Müllerian hormone in the SMAT-1 Sertoli cell line.

Belville C, Jamin SP, Picard JY, Josso N, di Clemente N.

Oncogene. 2005 Jul 21;24(31):4984-92.

PMID:
15897891
8.

Anti-Müllerian hormone and its receptors.

Josso N, di Clemente N, Gouédard L.

Mol Cell Endocrinol. 2001 Jun 20;179(1-2):25-32. Review.

PMID:
11420127
9.

Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regression.

Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR.

Mol Cell Endocrinol. 2003 Dec 15;211(1-2):15-9.

PMID:
14656471
10.

Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells.

Moore RK, Otsuka F, Shimasaki S.

J Biol Chem. 2003 Jan 3;278(1):304-10. Epub 2002 Nov 4.

11.

Transforming growth factor (TGF-beta)-specific signaling by chimeric TGF-beta type II receptor with intracellular domain of activin type IIB receptor.

Persson U, Souchelnytskyi S, Franzén P, Miyazono K, ten Dijke P, Heldin CH.

J Biol Chem. 1997 Aug 22;272(34):21187-94.

12.

Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-beta family.

Josso N, Clemente Nd.

Trends Endocrinol Metab. 2003 Mar;14(2):91-7. Review.

PMID:
12591180
13.

Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells.

Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM, Tran TT, Ha TU, Maheswaran S.

Mol Cell Endocrinol. 2003 Dec 15;211(1-2):43-9.

PMID:
14656475
14.

Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2.

Macías-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL.

J Biol Chem. 1998 Oct 2;273(40):25628-36.

15.

Bone morphogenetic protein-2 and -4 limit the number of enteric neurons but promote development of a TrkC-expressing neurotrophin-3-dependent subset.

Chalazonitis A, D'Autréaux F, Guha U, Pham TD, Faure C, Chen JJ, Roman D, Kan L, Rothman TP, Kessler JA, Gershon MD.

J Neurosci. 2004 Apr 28;24(17):4266-82.

16.

Ovarian granulosa cell tumors express a functional membrane receptor for anti-Müllerian hormone in transgenic mice.

Dutertre M, Gouédard L, Xavier F, Long WQ, di Clemente N, Picard JY, Rey R.

Endocrinology. 2001 Sep;142(9):4040-6.

PMID:
11517183
17.

Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.

Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.

Clin Cancer Res. 1999 Nov;5(11):3488-99.

18.

A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs).

Lin Y, Martin J, Gruendler C, Farley J, Meng X, Li BY, Lechleider R, Huff C, Kim RH, Grasser WA, Paralkar V, Wang T.

BMC Cell Biol. 2002 Jun 21;3:15.

19.

Autosomal recessive segregation of a truncating mutation of anti-Müllerian type II receptor in a family affected by the persistent Müllerian duct syndrome contrasts with its dominant negative activity in vitro.

Messika-Zeitoun L, Gouédard L, Belville C, Dutertre M, Lins L, Imbeaud S, Hughes IA, Picard JY, Josso N, di Clemente N.

J Clin Endocrinol Metab. 2001 Sep;86(9):4390-7.

PMID:
11549681
20.

Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription.

Ghosh-Choudhury N, Abboud SL, Nishimura R, Celeste A, Mahimainathan L, Choudhury GG.

J Biol Chem. 2002 Sep 6;277(36):33361-8. Epub 2002 Jun 25. Erratum in: J Biol Chem. 2003 May 2;278(18):16452.

Supplemental Content

Support Center